Skip to main content

Table 1 Neuropsychiatric and early PD/pre-PD treatments

From: Mesenchymal stromal cell biotherapy for Parkinson’s disease premotor symptoms

Symptom

Clinical intervention

Potential biotherapy

Other recommendation

 

Risk

 

Delivery path

Anxiety

Benzodiazepines (diazepam, lorazepam)

Lead to chronic stress that can worsen NMS

-

-

Further gut-brain axis modulation (gut microbiota with Lactobacillus plantarum PS128)

Cognitive impairment

Donepezil, galantamine, rivastigmine

Development of dementia

BMSC

Intravenous infusion

Increased adverse events (accidental falls, cognitive deterioration) with antipsychotics

Depression

Cognitive behavioral therapy, pramipexole, repetitive transcranial magnetic stimulation, venlafaxine

Prolongation of the Q-T interval when citalopram exceeds 20 mg in patients over 60 years old

NSC

Intravenous infusion

Sertraline, paroxetine, fluoxetine, citalopram with mild adverse reactions, contraindicated with monoamine oxidase B inhibitors MAO-BI. ECG monitoring is recommended

Hippocampal/NSC neurogenic compound NSI-189

Psychosis

Clozapine, pimavanserin

-

UC-MSC

Intravenous infusion

Regular blood routine monitoring is required

Impulse control disorder

Cognitive behavioral therapy

-

-

-

Dopamine agonist withdrawal syndrome should be monitored

Indifference

Piribedil

Comorbid depression, caregiver burden

-

-

Monitor patients for apathy after subthalamic nucleus deep brain stimulation surgery

Orthostatic hypotension

Droxidopa, fludrocortisone, midodrine

-

-

-

Moderate the use of diuretics, antidepressants, etc

Chronic constipation

Polyethylene glycol, probiotics/prebiotic fiber

-

Fecal microbiota transplantation

Upper gastrointestinal tract via nasoenteric tubes

Gut microbiota with probiotic supplements [8]

Anorexia, nausea, vomiting

Domperidone

-

-

-

Electrocardiogram needs to be monitored

Salivation

Ultrasound-guided botulinum toxin type A/B the injection to parotid gland/ submandibular gland

-

-

-

Chewing

Urinary dysfunction

Solifenacin

-

Myoblasts

Intrasphincteric injection

Anticholinergic (dry mouth, constipation) and non-cholinergic (indigestion, dizziness, headache) adverse reactions

Erectile dysfunction

Sildenafil

-

ASC

Intravenous infusion

Monitor orthostatic hypotension

Insomnia

Amantadine, eszopiclone, melatonin

-

-

-

Moderate the use of anti-PD drugs; continuous positive airway pressure for obstructive sleep apnea; further gut-brain axis modulation (gut microbiota with Lactobacillus fermentum PS150)

RBD

Clonazepam, melatonin

-

-

-

Moderate the use of SSRIs, SNRIs, TCAs, MAO-BI, or benzodiazepines

Pain

Opioids

-

-

-

Monitor constipation, gut microbiota with probiotic supplements, MSC-derived exosomes injection

Fatigue

Rasagiline

-

-

-

-

  1. Scales currently used to assess NMS in Parkinson’s patients include NMSQuest, NMSS, International Parkinson and Movement Disorder Society (MDS) unified PD rating scale (MDS-UPDRS), and other questionnaires/scales of symptom-specific assessment. NMSS has been widely used in clinical practice/trials since 2005, but with limitations, such as in anxiety, apathy, and depression, for the same domain, in fatigue and sleep disturbance for the same domain, missing drug-induced problems of non-motor fluctuations, and impulse control disorders with limited cognitive domains. The MDS-NMS scale since 2015 includes 52 items, involving 13 areas, and assessing the severity and frequency of NMS in Parkinson’ s patients with a score of 0 to 4. The subscales of this scale include eight items, which evaluate the degree of NMS changes related to the anti-PD drug treatment on a scale of 0 to 4. MDS-NMS scale is shown with the statistical analysis data with a valid measure of frequency of assessing impulse control disorders and related disorders, assessing cognitive and other neuropsychiatric aspects of PD. The non-motor fluctuations subscale assesses NMS in PD and the effect of fluctuating treatments